GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) major shareholder Francisco Partners Iv, L.P. sold 143,594 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $3.46, for a total value of $496,835.24. Following the transaction, the insider owned 706,649 shares in the company, valued at $2,445,005.54. This trade represents a 16.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Francisco Partners Iv, L.P. also recently made the following trade(s):
- On Wednesday, August 26th, Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total value of $4,536,619.50.
- On Tuesday, August 25th, Francisco Partners Iv, L.P. sold 127,273 shares of GoodRx stock. The shares were sold at an average price of $3.44, for a total value of $437,819.12.
- On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total value of $961,509.50.
- On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total value of $1,574,351.68.
- On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The shares were sold at an average price of $3.53, for a total value of $1,666,071.75.
GoodRx Stock Performance
NASDAQ GDRX opened at $3.53 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The company has a market cap of $1.21 billion, a P/E ratio of 88.27, a P/E/G ratio of 1.75 and a beta of 1.60. The stock has a 50-day moving average of $3.21 and a two-hundred day moving average of $2.67. GoodRx Holdings, Inc. has a 1-year low of $1.77 and a 1-year high of $5.81.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Technology Crossover Management X Ltd. acquired a new stake in shares of GoodRx in the 2nd quarter valued at $4,762,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of GoodRx during the fourth quarter worth $1,585,000. LSV Asset Management grew its stake in shares of GoodRx by 20.0% during the fourth quarter. LSV Asset Management now owns 2,825,900 shares of the company’s stock worth $7,658,000 after purchasing an additional 471,319 shares in the last quarter. Prescott Group Capital Management L.L.C. purchased a new position in GoodRx in the fourth quarter valued at $4,812,000. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in GoodRx by 10,242.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,502,666 shares of the company’s stock valued at $4,072,000 after buying an additional 1,488,137 shares during the last quarter. Hedge funds and other institutional investors own 63.77% of the company’s stock.
Analysts Set New Price Targets
Several equities analysts have commented on GDRX shares. Citigroup raised their price target on shares of GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded GoodRx from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. TD Cowen lifted their target price on GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. UBS Group boosted their target price on GoodRx from $2.50 to $3.75 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. Finally, Weiss Ratings upgraded GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, GoodRx currently has a consensus rating of “Hold” and a consensus target price of $4.23.
Get Our Latest Stock Report on GoodRx
GoodRx Company Profile
GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.
In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.
Read More
- Five stocks we like better than GoodRx
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.
